Exozymes Inc. participated in the Beryl Elites' 7th Annual Investment Conference on November 4, 2025, in New York City. CEO Michael Heltzen was featured as a panelist in the discussion titled "AI's Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact." Heltzen highlighted Exozymes' focus on leveraging AI to create new chemistries in drug discovery and development, aiming to generate competitive advantages and tangible impacts in the life sciences sector. The panel explored how machine learning is driving breakthroughs in biopharma, showcasing real-world applications and addressing industry challenges.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein.